Open AccessPhase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study
Author(s) -
Anton Hagenbeek,
Hans L. Mooij,
Josée M. Zijlstra,
Pieternella J. Lugtenburg,
Gustaaf van Imhoff,
Marcel Nijland,
Sanne H. Tonino,
Martin Hutchings,
Menno Spiering,
Roberto Liu,
Harm van Tinteren,
Marie José Kersten
Publication year - 2018
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2018.196899
Subject(s) - brentuximab vedotin , medicine , salvage therapy , refractory (planetary science) , cytarabine , dexamethasone , carmustine , oncology , cisplatin , lymphoma , de escalation , chemotherapy , hodgkin lymphoma , etoposide , physics , astrobiology